3 active not recruiting, 2 completed, 2 terminated, 1 recruiting. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Completed 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Active not recruiting 2, Completed 1 |
Follow Stage IIIA Colon Cancer AJCC v8: new trials by email Literature Review of Stage IIIA Colon Cancer AJCC v8 trials Research Report on Stage IIIA Colon Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 Balstilimab, Biospecimen Collection, Botensilimab - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 100 | 2026-07-01 | 2026-10-19 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial Genetic Testing - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Terminated | Academic and Community Cancer Research United | 199 | 2020-04-20 | 2025-08-29 | |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment Quality-of-Life Assessment, Questionnaire Administration - Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 565 | 2018-06-11 | 2026-09-25 |
Colonic Neoplasms (9) · Rectal Neoplasms (9) · Colorectal Neoplasms (6)
Colonic Diseases (9) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Gastrointestinal Diseases (9) · Gastrointestinal Neoplasms (9) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Neoplasms (9) · Neoplasms by Site (9) · Rectal Diseases (9) · Colorectal Neoplasms (3)
Nivolumab (2) · Trifluridine (2) · regorafenib (2) · trifluridine tipiracil drug combination (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Bevacizumab (1) · CTLA-4 Antigen (1) · Cetuximab (1) · Disulfides (1) · Genetic Testing (1) · Ipilimumab (1) · Irinotecan (1) · LY3214996 (1) · Magnetic Resonance Spectroscopy (1) · Panitumumab (1)
Academic and Community Cancer Research United (2) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · ECOG-ACRIN Cancer Research Group (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1)
United States (9)
John H Strickler (3) · Alisha Bent, MD (1) · Christine M Parseghian, MD (1) · Christos Fountzilas, MD (1) · Marwan G Fakih (1) · Pashtoon M Kasi (1) · Sheetal Kircher (1)
PMID 36892833, PMID 38194233, PMID 39244627, PMID 39287948, PMID 39652198
P30CA015083 (2), P30CA033572 (1), R01CA187238 (1), U10CA180820 (1), UG1CA189828 (1), UM1CA186704 (1)